Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond the initial analysis remained uncertain.
Introduction:
The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond the initial analysis remained uncertain. This post hoc analysis reports efficacy and safety after more than four years of follow-up.
Why was this study needed?:
. Long-term survival data for immunotherapy in advanced BTC were lacking.
. The durability of benefit with durvalumab beyond the primary analysis required confirmation.
. Long-term safety with prolonged immunotherapy exposure remained uncertain.
. Extended follow-up was needed to validate durvalumab plus GemCis as the standard first-line regimen.
Results:
After more than four years of follow-up, durvalumab plus GemCis continued to demonstrate a sustained overall survival advantage over chemotherapy alone. Long-term survival rates remained consistently higher with the addition of durvalumab, confirming durable clinical benefit in a subset of patients. Importantly, the safety profile remained stable over time, with no increase in treatment-related serious adverse events or treatment discontinuations compared with chemotherapy alone. These findings reinforce the long-term efficacy and tolerability of the regimen.
Clinical Impact:
This extended analysis provides compelling evidence that adding durvalumab to GemCis delivers durable survival benefits without compromising long-term safety. The persistence of a meaningful survival advantage beyond four years strengthens confidence in immunotherapy as the foundation of first-line treatment for advanced biliary tract cancer and provides reassurance regarding prolonged treatment outcomes.
Bottom Line:
More than four years of follow-up confirms that durvalumab plus gemcitabine–cisplatin provides durable survival benefit with a manageable long-term safety profile, reinforcing its role as the standard first-line treatment for advanced biliary tract cancer.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
Introduction: Cancer-associated cachexia is a devastating syndrome characterized by loss of appetite, weight loss, and muscle wasting, affecting up to half of patients with lung cancer. This landmark study uncovers a previously unrecognized mechanism linking...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.